Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human TNFSF15 Antibodies:
anti-Mouse (Murine) TNFSF15 Antibodies:
anti-Rat (Rattus) TNFSF15 Antibodies:
Go to our pre-filtered search.
Human Polyclonal TNFSF15 Primary Antibody for WB - ABIN2476844
Tinkanen, Kujansuu: Doppler ultrasound studies in pelvic inflammatory disease. in Gynecologic and obstetric investigation 1993
Show all 3 Pubmed References
Human Polyclonal TNFSF15 Primary Antibody for IF (p), IHC (p) - ABIN709556
?lebioda, Bojarska-Junak, Stanis?awowski, Cyman, Wierzbicki, Roli?ski, Celi?ski, Kmie?: TL1A as a potential local inducer of IL17A Expression in colon mucosa of inflammatory bowel disease patients. in Scandinavian journal of immunology 2015
TL1A modulated Rheumatoid arthritis-fibroblast-like synoviocytes migration and Indian hedgehog (show IHH Antibodies) signaling pathway using TNFR2 (show TNFRSF1B Antibodies).
TL1A can induce tumor cell proliferation and promote the occurrence of colitis-associated colorectal cancer by activating Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) pathway.
TNFSF15, a cytokine mainly produced by blood endothelial cells, facilitates tumor lymphangiogenesis by upregulating VEGFC (show VEGFC Antibodies) expression in A549 cells.
Results suggested that TNFSF15 (rs3810936 and rs4979462) SNPs may confer susceptibility to systemic lupus erythematosus (SLE) risk, which were significantly associated with the clinical phenotypes of SLE.
Three alternatively spliced isoforms of VEGI, VEGI174, VEGI192 and VEGI251 have been documented. This study investigated the effects of VEGI174 and its functional domains (V7 and V8) on epithelialmesenchymal transition (EMT (show ITK Antibodies)) in renal cell carcinoma (show MOK Antibodies) (RCC (show XRCC1 Antibodies)) cells in vitro. Overexpression of VEGI174, V7 or V8 inhibited EMT (show ITK Antibodies).
Results provide evidence that variance within TNFSF15 has the potential to affect cytokine expression across a range of tissues and thereby contribute to protection from infectious diseases such as leprosy, while increasing the risk of immune-mediated diseases including Crohn's disease and primary biliary cholangitis.
single variant analysis detected a previously unreported psoriasis risk locus at TNFSF15 (rs6478108)
the DR3 (show TNFRSF25 Antibodies)/TL1A pathway directly enhances human OC formation and resorptive activity, controlling expression and activation of CCL3 (show CCL3 Antibodies) and MMP-9 (show MMP9 Antibodies).
the blocking of tumor necrosis factor receptor 2 (TNFR2 (show TNFRSF1B Antibodies)) decreased TL1A-stimulated IL-6 (show IL6 Antibodies) production by rheumatoid arthritis fibroblast-like synoviocytes.
Distinct but overlapping TNFSF15 haplotypes were demonstrated in diverticulitis patients versus healthy controls when compared with the known Crohn's risk haplotype suggesting similar but distinct genetic predispositions. This study strengthens the role for a genetic predisposition to diverticulitis that involves the TNFSF15 gene.
TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis
ATF3 (show ATF3 Antibodies) protects against LPS (show TLR4 Antibodies)-induced acute lung injury by inhibiting TL1A expression.
This work describes both a novel function and essential requirement for the DR3 (show TNFRSF25 Antibodies)/TL1A pathway in acute, resolving, and chronic inflammation in the peritoneal cavity.
this study shows that TL1A-/- mice are more susceptible to dextran sodium sulfate colitis
These data demonstrated a direct role for TL1A-DR3 (show TNFRSF25 Antibodies) signaling in tissue fibrosis and that modulation of TL1A-DR3 (show TNFRSF25 Antibodies) signaling could inhibit gut (show GUSB Antibodies) fibrosis.
these data identify TL1A-DR3 (show TNFRSF25 Antibodies) interactions as a novel pathway that promotes Th9 differentiation and pathogenicity. TL1A may be a potential therapeutic target in diseases dependent on IL-9 (show IL9 Antibodies).
TL1A induces NF-kappaB (show NFKB1 Antibodies) activation in EC in renal and cardiac tissue from wild type but not DR3 (show TNFRSF25 Antibodies) knock-out mice.
TL1A deficiency impacts on the gut (show GUSB Antibodies) microbial composition and the mucosal immune system, especially the intraepithelial TCRgammadelta(+) T-cell subset, and that TL1A is involved in the establishment of adipose tissue.
Our data demonstrate a key role for TL1A in promoting ILC2s at mucosal barriers.
TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor (show FLT1 Antibodies) 1.
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Two transcript variants encoding different isoforms have been found for this gene.
tumor necrosis factor ligand superfamily member 15
, vascular endothelial growth inhibitor
, tocopherol (alpha) transfer protein-like
, TNF ligand-related molecule 1
, TNF superfamily ligand TL1A
, vascular endothelial cell growth inhibitor
, vascular endothelial growth inhibitor-192A
, bM20K13.3 (tumor necrosis factor (ligand) superfamily, member 15)